Zevra Therapeutics (ZVRA) Projected to Post Earnings on Thursday

Zevra Therapeutics (NASDAQ:ZVRA) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Zevra Therapeutics to post earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $8.15 on Wednesday. The firm has a fifty day simple moving average of $7.91 and a 200-day simple moving average of $8.20. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The stock has a market capitalization of $441.05 million, a price-to-earnings ratio of -4.14 and a beta of 1.98. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Analyst Ratings Changes

Several research firms have recently weighed in on ZVRA. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Guggenheim upped their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $22.29.

Insider Buying and Selling

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John B. Bode purchased 10,000 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $318,400. The trade was a 33.33 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. Corporate insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.